Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 108, Issue 3, 2014, Pages 176-178

  Rocio, Carolina ^a   Amato, Valdir Sabbaga ^a   Camargo, Raphael A ^a   Tuon, Felipe F ^b   Nicodemo, Antonio Carlos ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c NONE   (Brazil)

Author keywords

Amphotericin B; Leishmania treatment; Leishmaniasis

Indexed keywords

AMPHOTERICIN B; LEISHMANIA TREATMENT; LEISHMANIASIS;

ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEISHMANIASIS, MUCOCUTANEOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84894302196     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/tru011     Document Type: Article

References (5)

1. Amato VS, Tuon FF, Camargo RA et al. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 2011;85:818-9.
2. Sampaio RN, Marsden PD. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Rev Soc Bras Med Trop 1997;30:125-8.
3. Murray HW. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg 2012;86:434-40.
4. WHO. Control of the Leishmaniases. Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010. Geneva: World Health Organization. WHO Technical Report Series; 2010: p. 64.
5. Amato VS, Tuon FF, de Andrade HF Jr et al. Immunohistochemistry and polymerase chain reaction on paraffin-embedded material improve the diagnosis of cutaneous leishmaniasis in the Amazon region. Int J Dermatol 2009;48:1091-5.